Medical/Pharmaceuticals
WuXi XDC Launches New Commercial Manufacturing Facilities
* New commercial facilities offer one-stop manufacturing services for antibody intermediates, bioconjugate drug substance and drug product * Doubled capacity provides greater support to the rapidly growing global bioconjugate industry WUXI, China, Sept. 20, 2023 /PRNewswire/ -- WuXi XDC, a ...
2023-09-20 18:51
2578
The First Non-Vaccine Investigational Product for Cervical HSIL has Achieved Its Primary Endpoint
SHANGHAI, Sept. 20, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (Stock Code: 688176.SH), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, has announced that the multinatio...
2023-09-20 15:52
2559
Neusoft Holds the Top Market Share of Medical Imaging Information System in China
SHENYANG, China, Sept. 19, 2023 /PRNewswire/ -- Recently, IDC released the report "China's Medical Imaging Information System Market Share in 2022", in which Neusoft Corporation (Neusoft, SSE:600718) held the top market share in this sector due to its profound understanding of the market, continu...
2023-09-19 17:00
2859
Caliway Announces the Completion of Subject Recruitment in the CBL-0201EFP Phase 2-stage 2 Study Evaluating the CBL-514 in Cellulite Treatment
TAIPEI, Sept. 18, 2023 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway), a biopharmaceutical company focusing on breakthrough medical aesthetics and inflammatory medicine discovery of small-molecule therapeutics, announced the completion of subject recruitment in the CBL-0201EFP Phase 2-stage...
2023-09-19 11:16
2016
ST Pharm breaks ground on 2nd State-of-the-Art Oligonucleotide Facility
SEOUL, South Korea, Sept. 18, 2023 /PRNewswire/ -- ST Pharm successfully marked the completion of its groundbreaking ceremony, signaling a significant step forward in expanding its oligonucleotide manufacturing capacity and capabilities. The current expansion is in response to the growing demand...
2023-09-19 09:16
3647
VUNO's First AI-based Prospective Study Results Published in Critical Care
SEOUL, South Korea, Sept. 18, 2023 /PRNewswire/ -- VUNO Inc., South Korean medical AI company announced that its AI-based cardiac arrest risk management system, VUNO Med®-DeepCARS™, has proven its clinical validity for the first time through a prospective study utilizing Real World Data(RWD). <...
2023-09-18 21:00
3918
Acepodia Announces Nobel Laureate Carolyn Bertozzi, Ph.D., as Chief Scientific Advisor
ALAMEDA, Calif. and TAIPEI, Sept. 18, 2023 /PRNewswire/ -- Acepodia, a clinical stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) and allogeneic gamma delta 2 T-cell platforms to address gaps in cancer care, today announced that N...
2023-09-18 19:00
2035
Zylox-Tonbridge was Added to the FTSE Global Equity Index Series
HANGZHOU, China, Sept. 18, 2023 /PRNewswire/ -- Zylox-Tonbridge (2190.HK, "the Company") is pleased to learn that the Company's stock was added to the FTSE Global Equity Index Series ("GEIS"), including FTSE Global Total-Cap Index (LMSµ) and FTSE Global Micro Cap Index, according to the results o...
2023-09-18 14:51
4282
Samsung Biologics announces expanded strategic agreement with Bristol Myers Squibb to manufacture an antibody cancer drug substance
INCHEON, South Korea, Sept. 17, 2023 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS) announced today a new agreement with Bristol Myers Squibb (NYSE: BMY) for large-scale manufacturing of a Bristol Myers Squibb commercial antibody cancer drug substance. Bristol Myers Squibb and Samsung Biolog...
2023-09-18 07:57
2363
Cure Genetics and Frametact Reach a $60 Million Collaboration and Licensing Agreement for the Development of Gene Therapy for Familial Neurological Diseases
SUZHOU, China and HONG KONG, Sept. 14, 2023 /PRNewswire/ -- Cure Genetics and Frametact Limited, a biotech company specializing in researching and developing treatments for neurological diseases, jointly announce the signing of a collaborative development and licensing agreement. The partnership ...
2023-09-14 23:00
2871
Oscotec/ADEL Announce FDA Clearance of IND Application of ADEL-Y01 for the Treatment of Alzheimer's Disease
PANGYO, South Korea, Sept. 14, 2023 /PRNewswire/ -- Oscotec Inc. and ADEL Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application of ADEL-Y01 for the treatment of Alzheimer's disease (AD). Oscotec and ADEL are jointly developing ...
2023-09-14 20:00
2720
Porton Advanced and BRL Medicine Build Strategic Partnership to Accelerate Commercialization of Gene and Cell Therapies
SUZHOU, China, Sept. 14, 2023 /PRNewswire/ -- On September 13th, 2023, Porton Advanced Solutions (Porton Advanced) announced a strategic partnership with BRL Medicine Inc. (BRL Medicine). This collaboration will enhance the cell and gene therapy pipelines from BRL Medicine from clinical trials to...
2023-09-14 20:00
3198
Fujitsu and Baptist Health South Florida transform operating room scheduling with newly launched solution to boost utilization rates and the financial health of the surgical discipline
Recent trials with the solution delivered 37% improvement in available
prime-time minutes over a three-month period
TOKYO, Sept. 14, 2023 /PRNewswire/ -- Fujitsu today announced the launch of
an innovative solution to its Uvance Healthy Living
2023-09-14 18:03
2082
Dizal Announces China CDE Acceptance of New Drug Application for Golidocitinib for Relapsed or Refractory PTCL
SHANGHAI, Sept. 14, 2023 /PRNewswire/ -- Dizal today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for golidocitinib for the treatment of relapsed or refractory peripheral T-cell lymphom...
2023-09-14 17:07
2411
Asieris' New Drug APL-1401 Completes First Administration in Patient with Moderately to Severely Active UC
SHANGHAI, Sept. 14, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that its oral drug APL-1401 for the tr...
2023-09-14 16:54
2297
Nona Biosciences Expands Antibody Discovery Collaboration with BeiGene
CAMBRIDGE, Mass., Sept. 14, 2023 /PRNewswire/ -- Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited, committed to cutting edge antibody technology innovation and provider of integrated antibody discovery and development solutions from "Idea to IND" (I to I™), announced an agreeme...
2023-09-14 16:00
2044
S-Patch Ex, Wearable ECG Patch, Cleared by US FDA
* Lightest weighing ECG patch in the market designed for comfort and ease of use * Embedded with Samsung's Next-Generation bio-processor proven to capture world's most accurate ECG waveforms SEOUL, South Korea, Sept. 13, 2023 /PRNewswire/ -- Wellysis, a spin-off company from Samsung SDS, has ...
2023-09-13 21:00
3793
Asieris Announces Positive Interim Analysis Results in Phase II Clinical Trial of Oral APL-1202 in Combination with Tislelizumab, a PD-1 inhibitor, as Neoadjuvant Therapy for Muscle Invasive Bladder Cancer
SHANGHAI, Sept. 13, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that the clinical trial of oral APL-12...
2023-09-13 19:09
2235
J INTS BIO, WCLC 2023 - Presentation of Phase 1/2 study of 'JIN-A02', a Novel Oral 4th Generation EGFR TKI
SEOUL, South Korea, Sept. 13, 2023 /PRNewswire/ -- J INTS BIO announced that Phase 1/2 study of its novel, orally administered 4th generation EGFR-TKI 'JIN-A02' was presented at the 2023 IASLC World Conference on Lung Cancer held inSingapore from 9th to 12th September, during the official session...
2023-09-13 15:58
2318
Zuberitamab (Anruixi®), the first domestically developed anti-CD20 antibody as a Class I innovative drug from BioRay Pharmaceutical, has been approved for marketing in China
SHANGHAI, Sept. 13, 2023 /PRNewswire/ -- Recently, BioRay Pharmaceutical Co., Ltd. (hereinafter referred to as "Bioray") announced that its independently developed Class I innovative therapeutic biological product, Zuberitamab Injection (trade name: Anruixi®), indicated for the treatment of CD20...
2023-09-13 14:24
2092
Week's Top Stories
Most Reposted
Carro secures strategic investment from Orico
[Picked up by 290 media titles]
2026-09-18 16:29Agoda Begins Limited Public Beta of New AI Assistant That Turns Travel Ideas into Bookable Trips
[Picked up by 289 media titles]
2026-09-15 11:00
Avnet and The University of Hong Kong Open EMUS Lab to Accelerate AI Innovation and Commercialization in Hong Kong
[Picked up by 281 media titles]
2026-09-17 13:09
Tetra Pak and Soy Excellence Center Asia Host Regional Soy Food and Beverage Programme in Thailand
[Picked up by 268 media titles]
2026-09-18 11:51
Sovereign Investment Institutions Launch China-ASEAN Joint Investment Council
[Picked up by 267 media titles]
2026-09-16 09:09
Most Read
Agoda Begins Limited Public Beta of New AI Assistant That Turns Travel Ideas into Bookable Trips
2026-09-15 11:00
8392
QIVIKA to Launch Smart Scope on Kickstarter, Bringing a Professional Long-Range Experience to Day-and-Night Exploration
2026-09-12 09:00
7745
Temporal Raises $550 Million in Series E Round: NYSE Content Update
2026-09-14 21:14
6774
